Latest News
Kura Oncology reports early activity for darlifarnib–cabozantinib combination in cabozantinib‑pretreated ccRCC
...
European Commission approves Merck's ENFLONSIA for infant RSV prevention in Europe
17 April 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the European Commission has approved ENFLONSIA (clesrovimab) for the prevention of respiratory syncytial virus (...
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
17 April 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Friday that it has obtained Marketing Authorization in Denmark for Palbociclib Newbury tablets, marking the first approval within a Scandinavian regis...
Bold Therapeutics reports protection against chemotherapy-induced peripheral neuropathy with BOLD-100 anticancer agent
17 April 2026 - Canadian clinical-stage biopharmaceutical company Bold Therapeutics Inc on Thursday released new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects against chemotherapy-induced peripheral neur...
D2 Solutions acquires ProModRx
17 April 2026 - Healthcare consulting and technology company D2 Solutions announced on Thursday that it has acquired ProModRx, a cloud-based technology platform designed to help speed patient access to prescription medications.This acquisition aims t...